Journal of Controlled Release (IF:11.5) published a research paper on the treatment of oral squamous cell carcinoma with oncolytic bacteria SalMet-Vec®

On March 6, 2026, Guangzhou Sinogen Pharmaceutical Co., Ltd. (referred to as Sinogen) collaborated with researchers from institutions such as Southern Medical University and Guangdong University of Technology to publish an academic paper titled "Genetically Engineered Salmonella, SGN1, as a Tumor Microenvironment-Targeting Modality Capable of Methionine Reduction for Oral Squamous Cell Carcinoma" in the international journal *Journal of Controlled Release* (IF: 11.5). The study reported the pharmacological effect of the genetically engineered oncolytic bacteria SalMet-Vec®(SGN1), which specifically targets tumor methionine metabolism to inhibit the growth and metastasis of oral squamous cell carcinoma (OSCC). SGN1 offers a novel and effective therapeutic option for OSCC treatment, demonstrating significant potential for clinical translation.

Original link：

https://www.sciencedirect.com/science/article/abs/pii/S0168365926001835